Farhad Ravandi-Kashani, M.D.
Department of Leukemia, Division of Cancer Medicine
About Dr. Ravandi-Kashani
Dr. Farhad Ravandi is Janiece and Stephen A. Lasher Professor of Medicine and Chief of Section of Developmental Therapeutics in the Department of Leukemia at The University of Texas MD Anderson Cancer Center. He graduated from the University of London, England and undertook residency and fellowship training at the Baylor College of Medicine and The University of Texas MD Anderson Cancer Center. During this time he specialized in the management of hematological malignancies and stem cell transplantation. He then joined the University of Illinois at Chicago as the director of leukemia program and the interim director of stem cell transplant program for three years until he joined the Leukemia department of MD Anderson in 2003. Dr. Ravandi is board certified in Internal Medicine, Hematology and Medical Oncology. His main areas of interests are therapy of acute myeloid leukemia, as well as rare leukemias including Philadelphia positive acute lymphoblastic leukemia, hairy cell leukemia and T-cell leukemias. He has authored several book chapters and many articles in peer-reviewed journals. He is a member of several professional societies including the American Society of Hematology, American Society of Clinical Oncology, and Society of Hematological Oncology and is a member of editorial board of several journals.
Present Title & Affiliation
Primary Appointment
Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Chief, Section of Acute Myeloid Leukemia, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
Janiece and Stephen A. Lasher, Endowed Professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
Professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 1988 | St. Mary's Hospital Medical School/Imperial College, University of London, London, GB, Medicine, MBBS |
Postgraduate Training
| 1999-2000 | Fellow, Blood and Marrow Transplantation, Hematology/Stem Cell Transplantation, The University of Texas MD Anderson Cancer Center, Houston, Texas |
| 1997-1999 | Clinical Fellowship, Hematology/Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas |
| 1996-1997 | Clinical Residency, Hematology, Baylor College of Medicine, Houston, Texas |
| 1994-1996 | Clinical Residency, Internal Medicine, The University of Texas - Houston, Houston, Texas |
| 1989-1993 | Senior House Officer/Registrar, Emergency Medicine, Internal Medicine, Hematology, University of London, London |
Board Certifications
| 2000 | Hematology |
| 1999 | Medical Oncology |
| 1996 | American Board of Internal Medicine |
| 1993 | ECFMG |
| 1993 | FLEX |
Experience & Service
Academic Appointments
Associate Professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, 2007 - 2012
Assistant Professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, 2003 - 2007
Assistant Professor, Department of Stem Cell Transplant, Department of Hematology/Oncology, University of Illinois, College of Medicine, Chicago, IL, 2001 - 2003
Assistant Professor, Department of Hematology/Oncology, University of Illinois, College of Medicine, Chicago, IL, 2000 - 2003
Administrative Appointments/Responsibilities
Interim Director, Stem Cell Transplant Program, University of Illinois, Chicago, IL, 2002 - 2003
Director, Leukemia/Hematologic Malignancies Program, The University of Illinois, Chicago, IL, 2000 - 2003
Other Appointments/Responsibilities
Chief, Section of Developmental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, 2013 - 2019
Member, The European Leukemia Net MRD Working Group, Houston, TX, 2011 - Present
Member, Cancer and Leukemia Group B, Data Safety Monitoring Board, Houston, TX, 2011 - Present
Member, International Hairy Cell Leukemia Consortium, New York, NY, 2010 - Present
Member, Southwest Oncology Group Leukemia Committee, Houston, TX, 2009 - Present
Member, NCCN Acute Myeloid Leukemia committee, Houston, 2009 - Present
Member, Clinical Research Committee, Chicago, IL, 2001 - 2003
Institutional Committee Activities
Past Chair and Current Member, UT MD Anderson Institutional Research Grant, 2015 - Present
Member, Sisten Institution Network Funding Program Study Section Review Committee, 2011 - Present
Member, UT M. D. Anderson Clinical Research Committee II, 2005 - Present
Honors & Awards
| 2022 | UT MDACC Leukemia Fellowship- Mentor of the Year 2022, MD Anderson Cancer Center |
| 2000 | Travel award, Tenth annual Hematology/Oncology reviews, Mayo, Jacksonville |
| 1999 | Travel award, US National Medical Oncology Fellows’ Forum |
| 1999 | Travel award, Ninth annual Hematology/Oncology reviews, Mayo, Jacksonville |
| 1999 | Upjohn achievement in research award, M D Anderson Cancer Center |
| 1999 | Travel award, US National Medical Oncology Fellows' Forum, Ponte Verda Beach, March 2000 |
| 1999 | Travel award, Joint ASCO/AACR |
| 1999 | Selected to present in second foundations of cancer research symposium, UT M.D. Anderson Cancer Center |
| 1982 | Special paper in Biology, Lucton School |
Professional Memberships
Selected Publications
Peer-Reviewed Articles
- Ong, F, Kadia, TM, Short, NJ, Yilmaz, M, Alvarado, Y, Sasaki, K, Pierce, S, Garcia-Manero, G, DiNardo, C, Borthakur, G, Konopleva, M, Daver, N, Kantarjian, HM, Ravandi-Kashani, F. AML-513 The Role of FLT3 Inhibitors in Patients With Acute Myeloid Leukemia (AML) and T(6;9)(P22;Q34). Clinical Lymphoma, Myeloma and Leukemia 22:S258, 2022. e-Pub 2022. PMID: 36163855.
- Abuasab, T, Alvarado, Y, Issa, GC, Islam, R, James, N, Yilmaz, M, Jain, N, Masarova, L, Kornblau, SM, Jabbour, EJ, Pemmaraju, N, Montalban Bravo, G, Pierce, S, DiNardo, C, Kadia, TM, Daver, N, Konopleva, M, Garcia-Manero, G, Ravandi-Kashani, F. AML-328 Phase 2 Study of ASTX727 (Decitabine/Cedazuridine) Plus Venetoclax in Patients With Relapsed/Refractory Acute Myeloid Leukemia or Previously Untreated, Older Adult Patients Unfit for Chemotherapy. Clinical Lymphoma, Myeloma and Leukemia 22:S237, 2022. e-Pub 2022. PMID: 36163813.
- Ravandi-Kashani, F, Wei, A, Döhner, H, Sayar, H, Montesinos, P, Dombret, H, Selleslag, D, Porkka, K, Jang, JH, Skikne, B, Beach, CL, Tian, Y(, Roboz, G. AML-457 Oral Azacitidine (Oral-AZA) in Patients With Acute Myeloid Leukemia (AML) in First Remission after Intensive Chemotherapy (IC). Clinical Lymphoma, Myeloma and Leukemia 22:S252-S253, 2022. e-Pub 2022. PMID: 36163843.
- Ravandi F. EXABS-149-AML Is All Oral Therapy of AML a Reality for the Future?. Clin Lymphoma Myeloma Leuk 22 Suppl 2:S58, 2022. e-Pub 2022. PMID: 36164230.
- Ravandi F. Are We Witnessing a Paradigm Shift in the Treatment of Acute Myeloid Leukemia?. Cancer J 28(1):1, 2022. e-Pub 2022. PMID: 35072367.
- Ohanian M, Garcia-Manero G, Levis M, Jabbour E, Daver N, Borthakur G, Kadia T, Pierce S, Burger J, Richie MA, Patel K, Andreeff M, Estrov Z, Cortes J, Kantarjian H, Ravandi F. Sorafenib Combined with 5-azacytidine in Older Patients with Untreated FLT3-ITD Mutated Acute Myeloid Leukemia. Am J Hematol 93(9):1136-1141, 2018. e-Pub 2018. PMID: 30028037.
- Ravandi F, Ritchie EK, Sayar H, Lancet JE, Craig MD, Vey N, Strickland SA, Schiller GJ, Jabbour E, Pigneux A, Horst HA, Récher C, Klimek VM, Cortes JE, Carella AM, Egyed M, Krug U, Fox JA, Craig AR, Ward R, Smith JA, Acton G, Kantarjian HM, Stuart RK. Phase 3 results for vosaroxin/cytarabine in the subset of patients =60 years old with refractory/early relapsed acute myeloid leukemia. Haematologica. e-Pub 2018. PMID: 29794146.
- Benton CB, Ravandi F. A mind map for managing minimal residual disease in acute myeloid leukemia. Clin Adv Hematol Oncol 15(11):859-867, 2017. e-Pub 2017. PMID: 29200419.
- Naqvi K, Konopleva M, Ravandi F. Targeted therapies in Acute Myeloid Leukemia: a focus on FLT-3 inhibitors and ABT199. Expert Rev Hematol. e-Pub 2017. PMID: 28799432.
- Ravandi F, Stone R. Acute Promyelocytic Leukemia: A Perspective. Clin Lymphoma Myeloma Leuk. e-Pub 2017. PMID: 28735889.
- Daver N, Kantarjian H, Garcia-Manero G, Jabbour E, Borthakur G, Brandt M, Pierce S, Vaughan K, Ning J, Nogueras González GM, Patel K, Jorgensen J, Pemmaraju N, Kadia T, Konopleva M, Andreeff M, DiNardo C, Cortes J, Ward R, Craig A, Ravandi F. Vosaroxin in combination with decitabine in newly diagnosed older patients with acute myeloid leukemia or high-risk MDS. Haematologica. e-Pub 2017. PMID: 28729302.
- Short NJ, Kantarjian H, Jabbour E, Cortes JE, Thomas DA, Rytting ME, Daver N, Alvarado Y, Konopleva M, Kebriaei P, Wierda WG, DiNardo CD, Bivins C, McCue D, Richie MA, Ravandi F. A phase I study of moxetumomab pasudotox in adults with relapsed or refractory B-cell acute lymphoblastic leukaemia. Br J Haematol. e-Pub 2017. PMID: 28616864.
- Sasaki K, Jabbour E, Cortes J, Kadia T, Garcia-Manero G, Borthakur G, Jain P, Pierce S, Daver N, Takahashi K, O'Brien S, Kantarjian H, Ravandi F. Outcome of Patients With Therapy-Related Acute Myeloid Leukemia With or Without a History of Myelodysplasia. Clin Lymphoma Myeloma Leuk 16(11):616-624, 2016. e-Pub 2016. PMID: 27601000.
- Sanford D, Ravandi F. Management of Newly Diagnosed Acute Myeloid Leukemia in the Elderly: Current Strategies and Future Directions. Drugs Aging 32(12):983-97, 2015. e-Pub 2015. PMID: 26446152.
- Badar T, Shetty A, Bueso-Ramos C, Cortes J, Konopleva M, Borthakur G, Pierce S, Huang X, Chen HC, Kadia T, Daver N, Dinardo C, O'Brien S, Garcia-Manero G, Kantarjian H, Ravandi F. Bone marrow necrosis in acute leukemia: Clinical characteristic and outcome. Am J Hematol 90(9):769-73, 2015. e-Pub 2015. PMID: 26017166.
- Kadia TM, Ravandi F, Cortes J, Kantarjian H. Toward Individualized Therapy in Acute Myeloid Leukemia: A Contemporary Review. JAMA Oncol 1(6):820-8, 2015. e-Pub 2015. PMID: 26181162.
- Kadia T, Kantarjian H, Garcia-Manero G, Borthakur G, Wang X, Patel K, Jabbour E, Brandt M, Daver N, Pemmaraju N, Pierce S, Cortes J, Ravandi F. Prognostic significance of the Medical Research Council cytogenetic classification compared with the European LeukaemiaNet risk classification system in acute myeloid leukaemia. Br J Haematol 170(4):590-3, 2015. e-Pub 2015. PMID: 25716073.
- DiNardo CD, Ravandi F, Agresta S, Konopleva M, Takahashi K, Kadia T, Routbort M, Patel KP, Brandt M, Pierce S, Garcia-Manero G, Cortes J, Kantarjian H. Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML. Am J Hematol 90(8):732-6, 2015. e-Pub 2015. PMID: 26016821.
- Takahashi K, Roh W, Zhang J, Propotopov A, Patel K, Strickland S, Kim A, Vnencak-Jones C, Pelletier S, Parmar S, Garcia-Manero G, Kornblau S, Chin L, Kantarjian H, Futreal PA, Ravandi F. Clonal evolution of acute myeloid leukemia relapsed after 19 years of remission. Am J Hematol 90(7):E134-5, 2015. e-Pub 2015. PMID: 25801490.
- Badar T, Ravandi F. Relapsed Acute Myeloid Leukemia: Need for Innovative Treatment Strategies to Improve Outcome. Clin Lymphoma Myeloma Leuk 15 Suppl:S104-8, 2015. e-Pub 2015. PMID: 26297261.
- Stuart RK, Cripe LD, Maris MB, Cooper MA, Stone RM, Dakhil SR, Turturro F, Stock W, Mason J, Shami PJ, Strickland SA, Costa LJ, Borthakur G, Michelson GC, Fox JA, Leavitt RD, Ravandi F. REVEAL-1, a phase 2 dose regimen optimization study of vosaroxin in older poor-risk patients with previously untreated acute myeloid leukaemia. Br J Haematol 168(6):796-805, 2015. e-Pub 2015. PMID: 25403830.
- Roboz GJ, Khoury HJ, Jabbour E, Session W, Ritchie EK, Miao H, Faderl S, Zheng W, Feldman EJ, Arellano M, Morrison JG, Ravandi F. Phase I trial of SAR103168, a novel multi-kinase inhibitor,in patients with refractory/relapsed acute leukemias or high-risk myelodysplastic syndromes. Leuk Lymphoma 56(2):395-400, 2015. e-Pub 2015. PMID: 24794806.
- Benton CB, Ravandi F, Andreeff M, Kadia T, Ruvolo V, Qiu P, Wheeler DA, Garcia-Manero G, Cortes J, Kantarjian HM, Konopleva M. Case series of AML patients receiving hypomethylation therapy and retrospectively found to have IDH1 or IDH2 mutations. Leuk Lymphoma 55(6):1431-4, 2014. e-Pub 2014. PMID: 24033106.
- Jain P, Kantarjian H, Patel K, Faderl S, Garcia-Manero G, Benjamini O, Borthakur G, Pemmaraju N, Kadia T, Daver N, Nazha A, Luthra R, Pierce S, Cortes J, Ravandi F. Mutated NPM1 in patients with acute myeloid leukemia in remission and relapse. Leuk Lymphoma 55(6):1337-44, 2014. e-Pub 2014. PMID: 24004182.
- Raza A, Ravandi F, Rastogi A, Bubis J, Lim SH, Weitz I, Castro-Malaspina H, Galili N, Jawde RA, Illingworth A. A prospective multicenter study of paroxysmal nocturnal hemoglobinuria cells in patients with bone marrow failure. Cytometry B Clin Cytom 86(3):175-82, 2014. e-Pub 2014. PMID: 24227693.
- Benjamini O, Dumlao TL, Kantarjian H, O'Brien S, Garcia-Manero G, Faderl S, Jorgensen J, Luthra R, Garris R, Thomas D, Kebriaei P, Champlin R, Jabbour E, Burger J, Cortes J, Ravandi F. Phase II trial of hyper CVAD and dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemia. Am J Hematol 89(3):282-7, 2014. e-Pub 2014. PMID: 24779033.
- Raza A, Ravandi F, Rastogi A, Bubis J, Lim SH, Weitz I, Castro-Malaspina H, Galili N, Jawde RA, Illingworth A. A Prospective Multicenter Study of Paroxysmal Nocturnal Hemoglobinuria Cells in Patients with Bone Marrow Failure. Cytometry B Clin Cytom. e-Pub 2013. PMID: 24127323.
- Cardenas-Turanzas M, Ravandi-Kashani F, Cortes JE, Jabbour E, Faderl S, Pierce SA, Kantarjian H. Expectations of serious adverse events at the end of life of patients with acute myeloid leukemia who receive salvage therapy. Clin Lymphoma Myeloma Leuk 13(5):579-83, 2013. e-Pub 2013. PMID: 23763918.
- Chen Y, Kantarjian H, Pierce S, Faderl S, O'Brien S, Qiao W, Abruzzo L, de Lima M, Kebriaei P, Jabbour E, Daver N, Kadia T, Estrov Z, Garcia-Manero G, Cortes J, Ravandi F. Prognostic significance of 11q23 aberrations in adult acute myeloid leukemia and the role of allogeneic stem cell transplantation. Leukemia 27(4):836-42, 2013. e-Pub 2013. PMID: 23135353.
- Nazha A, Bueso-Ramos C, Estey E, Faderl S, O'Brien S, Fernandez MH, Nguyen M, Koller C, Freireich E, Beran M, Pierce S, Keating M, Cortes J, Kantarjian H, Ravandi F. The Addition of All-Trans Retinoic Acid to Chemotherapy May Not Improve the Outcome of Patient with NPM1 Mutated Acute Myeloid Leukemia. Front Oncol 3:218, 2013. e-Pub 2013. PMID: 24032106.
- Chen Y, Kantarjian H, Wang H, Cortes J, Ravandi F. Acute promyelocytic leukemia: A population-based study on incidence and survival in the United States, 1975-2008. Cancer 118(23):5811-8, 2012. e-Pub 2012. PMID: 22707337.
- Quintás-Cardama A, Ravandi F, Liu-Dumlao T, Brandt M, Faderl S, Pierce S, Borthakur G, Garcia-Manero G, Cortes J, Kantarjian H. Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia. Blood 120(24):4840-5, 2012. e-Pub 2012. PMID: 23071272.
- Kadia TM, Kantarjian H, Kornblau S, Borthakur G, Faderl S, Freireich EJ, Luthra R, Garcia-Manero G, Pierce S, Cortes J, Ravandi F. Clinical and proteomic characterization of acute myeloid leukemia with mutated RAS. Cancer 118(22):5550-9, 2012. e-Pub 2012. PMID: 22569880.
- Boumber Y, Kantarjian H, Jorgensen J, Wen S, Faderl S, Castoro R, Autry J, Garcia-Manero G, Borthakur G, Jabbour E, Estrov Z, Cortes J, Issa JP, Ravandi F. A randomized study of decitabine versus conventional care for maintenance therapy in patients with acute myeloid leukemia in complete remission. Leukemia 26(11):2428-31, 2012. e-Pub 2012. PMID: 22665218.
- Ohanian M, Leventaki V, Verstovsek S, Estrov Z, Lin P, Yin C, Kantarjian H, Huh Y, Ravandi F. Acute lymphoblastic leukemia arising in post - Polycythemic myelofibrosis, A rare entity. Leuk Lymphoma 53(9):1839-41, 2012. e-Pub 2012. PMID: 22303899.
- Sharma M, Ravandi F, Bayraktar UD, Chiattone A, Bashir Q, Giralt S, Chen J, Qazilbash M, Kebriaei P, Konopleva M, Andreeff M, Cortes J, McCue D, Kantarjian H, Champlin RE, de Lima M. Treatment of FLT3-ITD Positive Acute Myeloid Leukemia Relapsing After Allogeneic Stem Cell Transplantation with Sorafenib. Biol Blood Marrow Transplant 17(12):1874-7, 2011. e-Pub 2011. PMID: 21767516.
- Mathisen MS, Ravandi F. Horse versus rabbit antithymocyte globulin in aplastic anemia. N Engl J Med 365(19):1842; author reply 1843-4, 2011. e-Pub 2011. PMID: 22070488.
- Mathisen MS, O'Brien S, Thomas D, Cortes J, Kantarjian H, Ravandi F. Role of tyrosine kinase inhibitors in the management of Philadelphia chromosome-positive acute lymphoblastic leukemia. Curr Hematol Malig Rep 6(3):187-94, 2011. e-Pub 2011. PMID: 21660654.
- Prescott H, Kantarjian H, Cortes J, Ravandi F. Emerging FMS-like tyrosine kinase 3 inhibitors for the treatment of acute myelogenous leukemia. Expert Opin Emerg Drugs 16(3):407-23, 2011. e-Pub 2011. PMID: 21417961.
- Lancet JE, Ravandi F, Ricklis RM, Cripe LD, Kantarjian HM, Giles FJ, List AF, Chen T, Allen RS, Fox JA, Michelson GC, Karp JE. A phase Ib study of vosaroxin, an anticancer quinolone derivative, in patients with relapsed or refractory acute leukemia. Leukemia. e-Pub 2011. PMID: 21760592.
- Levis M, Ravandi F, Wang ES, Baer MR, Perl A, Coutre S, Erba H, Stuart RK, Baccarani M, Cripe LD, Tallman MS, Meloni G, Godley LA, Langston AA, Amadori S, Lewis ID, Nagler A, Stone R, Yee K, Advani A, Douer D, Wiktor-Jedrzejczak W, Juliusson G, Litzow MR, Petersdorf S, Sanz M, Kantarjian HM, Sato T, Tremmel L, Bensen-Kennedy DM, Small D, Smith BD. Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse. Blood 117(12):3294-301, 2011. e-Pub 2011. PMID: 21270442.
- Santos FP, Kantarjian H, Garcia-Manero G, Ravandi F. The search for better prognostic models in myelodysplastic syndromes. Curr Hematol Malig Rep 6(1):13-21, 2011. e-Pub 2011. PMID: 21136214.
- Santos FP, Bueso-Ramos CE, Ravandi F. Acute erythroleukemia: diagnosis and management. Expert Rev Hematol 3(6):705-18, 2010. e-Pub 2010. PMID: 21091147.
- Rytting M, Ravandi F, Estey E, Cortes J, Faderl S, Garcia-Manero G, Jeha S, Ouzounian S, Pierce S, Kantarjian H. Intensively timed combination chemotherapy for the induction of adult patients with acute myeloid leukemia: long-term follow-up of a phase 2 study. Cancer 116(22):5272-8, 2010. e-Pub 2010. PMID: 20665501.
- Kantarjian H, Ravandi F, O'Brien S, Cortes J, Faderl S, Garcia-Manero G, Jabbour E, Wierda W, Kadia T, Pierce S, Shan J, Keating M, Freireich EJ. Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia. Blood 116(22):4422-9, 2010. e-Pub 2010. PMID: 20668231.
- Santos FP, Faderl S, Garcia-Manero G, Koller C, Beran M, O'Brien S, Pierce S, Freireich EJ, Huang X, Borthakur G, Bueso-Ramos C, de Lima M, Keating M, Cortes J, Kantarjian H, Ravandi F. Adult acute erythroleukemia: an analysis of 91 patients treated at a single institution. Leukemia 23(12):2275-80, 2009. e-Pub 2009. PMID: 19741728.
- De Padua Silva L, de Lima M, Kantarjian H, Faderl S, Kebriaei P, Giralt S, Davisson J, Garcia-Manero G, Champlin R, Issa JP, Ravandi F. Feasibility of allo-SCT after hypomethylating therapy with decitabine for myelodysplastic syndrome. Bone Marrow Transplant 43(11):839-43. e-Pub 2009. PMID: 19151791.
- Aribi A, Huh Y, Keating M, O'Brien S, Faderl S, Ferrajoli A, Wierda W, Kantarjian H, Ravandi F. T-Cell large granular lymphocytic leukemia: experience in a single institution over eight years. Leuk Res 31(7):939-945, 2007. e-Pub 2007.
- Aribi A, Bueso-Ramos C, Estey E, Estrov Z, O'Brien S, Giles F, Faderl S, Thomas D, Kebriaei P, Garcia-Manero G, Pierce S, Cortes J, Kantarjian H, Ravandi F. Biphenotypic acute leukemia: A case series. Br J Haematol 138(2):213-216, 2007. e-Pub 2007.
- Beinart G, Jones D, Abruzzo LV, Ravandi F. Spontaneous hematologic and cytogenetic remission in a case of acute myelogenous leukemia with inversion 16. Clinical Leukemia 1, No. 4:243-246, 2007. e-Pub 2007.
- Kadkol SS, Bruno A, Dodge C, Lindgren V, Ravandi F. Comprehensive analysis of CBFbeta-MYH11 fusion transcripts in acute myeloid leukemia by RT-PCR analysis. J Mol Diagn 6(1):22-7, 2004. e-Pub 2004. PMID: 14736823.
- de Lima M, Ravandi F, Shahjahan M, Andersson B, Couriel D, Donato M, Khouri I, Gajewski J, van Besien K, Champlin R, Giralt S, Kantarjian H. Long-term follow-up of a phase I study of high-dose decitabine, busulfan, and cyclophosphamide plus allogeneic transplantation for the treatment of patients with leukemias. Cancer 97(5):1242-7, 2003. e-Pub 2003. PMID: 12599231.
- Damle B, Ravandi F, Kaul S, Sonnichsen D, Ferreira I, Brooks D, Stewart D, Alberts D, Pazdur R. Effect of food on the oral bioavailability of UFT and leucovorin in cancer patients. Clin Cancer Res 7(3):517-23, 2001. e-Pub 2001. PMID: 11297242.
- Lynott A, Ravandi-Kashani F, Giles FJ. Malignancy: Case Report: Hypereosinophilia Progressing to Granulocytic Sarcoma and Acute Myelocytic Leukemia with Trisomy 8: A Case Report and Review of the Literature. Hematology 4(6):487-493, 2000. e-Pub 2000. PMID: 11399591.
- Lynott A, Ravandi-Kashani F, Giles FJ. Hypereosinophilia Progressing to Granulocytic Sarcoma and Acute Myelocytic Leukemia with Trisomy 8: A Case Report and Review of the Literature. Hematology 4(6):487-93, 1999. e-Pub 1999. PMID: 27420743.
- Ravandi F. Primary refractory AML: In search of better definitions and better therapies. British Journal of Haematology.
Other Articles
- Kantarjian, HM, DiNardo, C, Kadia, TM, Daver, N, Altman, JK, Stein, EM, Jabbour, EJ, Schiffer, CA, Lang, A, Ravandi-Kashani, F Acute myeloid leukemia management and research in 2025. Ca-A Cancer Journal for Clinicians 75(1):46-67, 2025. PMID: 39656142.
- Babakhanlou R, Ravandi-Kashani F, Hita AG, Kontoyiannis DP Anorectal Infections in Neutropenic Leukemia Patients: A Common Clinical Challenge. J Hematol 13(1-2):1-11, 2024. PMID: 38644983.
- Babakhanlou R, Ravandi-Kashani F, Kontoyiannis DP Neutropenic Enterocolitis: An Uncommon, but Fearsome Complication of Leukemia. J Hematol 12(2):59-65, 2023. PMID: 37187499.
- Babakhanlou R, Ravandi-Kashani F Non-intensive acute myeloid leukemia therapies for older patients. Expert Rev Hematol 16(3):171-180, 2023. PMID: 36864772.
- Babakhanlou R, Ravandi-Kashani F SOHO State of the Art Updates and Next Questions |The Role of Maintenance Therapy in Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk 23(1):1-7, 2023. PMID: 36456394.
- Ramos Perez J, Ravandi-Kashani F The pharmacological management of hairy cell leukemia. Expert Opin Pharmacother 21(11):1337-1344, 2020. PMID: 32378970.
- Assi R, Ravandi F FLT3 inhibitors in acute myeloid leukemia: Choosing the best when the optimal does not exist. Am J Hematol 93(4):553-563, 2018. PMID: 29285788.
- Short NJ, Kantarjian H, Jabbour E, Ravandi F Which tyrosine kinase inhibitor should we use to treat Philadelphia chromosome-positive acute lymphoblastic leukemia?. Best Pract Res Clin Haematol 30(3):193-200, 2017. PMID: 29050692.
- Kadia TM, Ravandi F, Cortes J, Kantarjian H New drugs in acute myeloid leukemia. Ann Oncol 27(5):770-8, 2016. PMID: 26802152.
- Garg R, Faderl S, Garcia-Manero G, Cortes J, Koller C, Huang X, York S, Pierce S, Brandt M, Beran M, Borthakur G, Kantarjian H, Ravandi F Phase II study of rabbit anti-thymocyte globulin, cyclosporine and granulocyte colony-stimulating factor in patients with aplastic anemia and myelodysplastic syndrome. Leukemia 23(7):1297-302. PMID: 19242494.
Editorials
- Ravandi-Kashani, F. Therapeutic Advances and Future of Therapy in Acute Myeloid Leukemia. American journal of hematology 100(S2):3-4, 2025. PMID: 39960014.
Abstracts
- Ohanian, M, Garcia-Manero, G, Jabbour, EJ, Daver, N, Borthakur, G, Kadia, TM, Brandt, M, Pierce, S, Burger, J, Richie, MA, Patel, K, Cortes, JE, Kantarjian, HM, Ravandi, F. Combination of Sorafenib and 5-Azacytidine in Older Patients with Untreated Acute Myeloid Leukemia with FLT3-ITD mutation. Blood 22(128):1611, 2016. e-Pub 2016.
- Abaza, Y, Kantarjian, HM, Jabbour, EJ, Thomas, DA, Kadia, TM, Borthakur, G, Burger, J, Wierda, WG, Jain, N, Faderl, S, O'Brien, SM, Konopleva, M, Ferrajoli, A, Kornblau, SM, Daver, N, Pemmaraju, N, Bose, P, Thompson, PA, Kelly, MA, Garris, R, Garcia-Manero, G, Cortes, JE, Ravandi, F. Phase II Study of Hyper-CVAD Plus Nelarabine in Previously Untreated Adult T-Cell Acute Lymphoblastic Leukemia and T-Lymphoblastic Lymphoma. Blood 22(128):177, 2016. e-Pub 2016.
- Daver N, Kantarjian HM, Garcia-Manero G, Pemmaraju N, Kadia T, DiNardo CD, Jain N, Borthakur G, Jabbour E, Konopleva M, Cortes JE, Craig A, Ravandi F. Phase I/II Study of Vosaroxin and Decitabine in Newly Diagnosed Older Patients (pts) with Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS). Blood 124(21), 2014. e-Pub 2014.
- Estey E, Thall P, Wang X, Borthakur G, Ravandi-Kashani F. Effect of delaying therapy in newly diagnosed AML. Proc Am Soc Clin Oncol 25:362, 2007. e-Pub 2007.
- Aribi A, Kantarjian H, O'Brien S, Koller C, Verstovsek S, Faderl S, Keating M, Ravandi-Kashani F. Combination therapy with alemtuzumab and pentostatin is effective and has acceptable toxicity in patients with T-lymphoid neoplasms. Proc Am Soc clin Oncol 25:367, 2007. e-Pub 2007.
- Solh MM, Kantarjian H, O'Brien S, Giles F, Faderl S, Garcia-Manero G, Rios M, Shan J, Cortes J, Ravandi-Kashani F. Central nervous system (CNS) leukemia after imatinib mesylate therapy for chronic myelogenous leukemia (CML). Proc Am Soc Clin Oncol 25:367, 2007. e-Pub 2007.
- Borthakur G, Ravandi-Kashani F, Cortes J, Jabbour E, Faderl S, O'Brien S, Verstovsek S, Garcia-Manero G, Newman BA, Giles F, Issa JP, Kantarjian HM. Decitabine induces responses in patients with myelodysplastic syndrome (MDS) after failure of azacitidine therapy. Blood 108:157a, 2006. e-Pub 2006.
- O'Brien S, Ravandi-Kashani F, Wierda, WG, Giles F, Thomas D, Huang X, Riehl TD, Tarrand JJ, Brandi O, Kantarjian HM, Keating MJ. A randomized trial of valacyclovir versus valganciclovir to prevent CMV reactivation in patients with CLL receiving alemtuzumab. Blood 106:830a, 2005. e-Pub 2005.
- Aribi A, Keating M, O'Brien S, Ferrajoli A, Faderl S, Lerner S, Koller C, Wierda W, Cortes J, Kantarjian H, Ravandi-Kashani F. Long-term follow-up of patients with T-large granular lymphocyte leukemia (T-LGL); Experience in a single institution. Blood 106:338b, 2005. e-Pub 2005.
- Tabandeh H, Ravandi-Kashani F, Marks V. Subtle changes in visual function during hypoglycemia. British Diabetic Association Conference, 1992. e-Pub 1992.
Letters to the Editor
- Ravandi F. Reply to Evaluation of PML Immunofluorescence, flow cytometric immunophenotypic analysis, and reverse transcriptase polymerase chain reaction for PML/RARa for rapid diagnosis of acute promyelocytic leukemia. Cancer.
Selected Presentations & Talks
Local Presentations
- 2017. Monoclonal antibodies in AML. Conference. MD Anderson. Houston, TX, US.
- 2015. How I Treat AML. Conference. SOHO 2015. Houston, TX, US.
- 2014. Progress in the Treatment of AML in the Genomics Era. Conference. Medical Word Americas. Houston, TX, US.
- 2013. Clinical Implications of Molecular Data in the Therapy of Acute Leukemia. Conference. MD Anderson Cancer Center. Houston, TX, US.
- 2013. Progress in Therapy of Patients with AML. Conference. MD Anderson Cancer Center. Houston, TX, US.
- 2013. Beyond Anthracyclines in the Managements of AML. Conference. MD Anderson Cancer Center. Houston, TX, US.
- 2012. Treatment of AML at MD Anderson. Conference. MD Anderson Cancer Center. Houston, TX, US.
- 2012. Update of Chemo Rx + TKIs in Ph-positive ALL. Conference. MD Anderson Cancer Center. Houston, TX, US.
- 2012. Treatment of Elderly AML. Conference. MD Anderson Cancer Center. Houston, TX, US.
Regional Presentations
- 2017. Mylotarg and other CD33 ADCs. Conference. Think Tank, US.
- 2013. Hematological Malignancies. Conference. Nebraska Methodist College. Omaha, NE, US.
- 2010. Treatment of Elderly Patients with AML. Conference. Genzyme Advisory Board. Dallas, TX, US.
- 2009. Role of Arsenic Trioxide in Treating APL. Conference. Cephalon Advisory Board. Miami, FL, US.
- 2009. Treatment of Elderly Patients with AML. Conference. Genzyme Advisory Board. Chicago, IL, US.
- 2008. Role of Decitabine in Maintenance Therapy of AML. Conference. Eisai Advisory Board. Tampa, FL, US.
- 2005. Treatment of aplastic anemia using thymoglobulin. Conference. Genzyme. Atlanta, GA, US.
- 2005. Management of Patients with MDS. Conference. Genzyme MSL Meeting. West Palm Beach, FL, US.
National Presentations
- 2017. Acute Lymphocytic Leukemia: New Approaches in Management. Conference. American Society of Hematology. Atlanta, GA, US.
- 2017. Mutational Testing to Select Novel Targeted Therapies for AML. Invited. Medscape Video Spotlight. Boston, MA, US.
- 2017. Panel Targeted STrategies and Use in front-line and Ph+ ALL. Invited. Live Medical Crossfire: Expert Exchanges in Hematologic Malignancies. New York, NY, US.
- 2017. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Novel Targeted and Immune-based Approaches in the Treatment of AML. Conference. American Society of Hematology. Atlanta, GA, US.
- 2016. Durable Overall Survival Benefit in Patients ≥ 60 Years with Relapsed or Refractory AML Treated with Vosaroxin/Cytarabine Vs Placebo/Cytarabine: Updated Results from the Valor Trial. Conference. American Society of Hematology. San Diego, CA, US.
- 2014. Advances and Controversies in the Biology and Therapy of Acute Leukemia and Myelodysplasia. Invited. Acute Leukemia Forum 2014. San Francisco, CA, US.
- 2014. Acute Leukemia. Invited. Lymphoma Study Group/Hematology Highlights: A Post ASH Review. Omaha, NE, US.
- 2013. Understanding Evolving Treatment Paradigms for Older Adults with Acute Myeloid Leukemia. Conference. Good Samaritan Medical Center. West Palm Beach, FL, US.
- 2013. Acute Leukemias. Invited. 2013 CTCA Review Advances & controversies in Hematology & Oncology, US.
- 2013. Current clinical trials in HCL at MD Anders. Conference. Hairy Cell Leukemia Consortium. New York, NY, US.
- 2013. Relapse AMLE: Why no standard of care?. Invited. Acute Leukemia Forum 2013. San Francisco, CA, US.
- 2013. ASH 2012: Summary of Presentations in AML. Invited. Nebraska Oncology Society Membership. Omaha, NE, US.
- 2012. Data on Treatment Options for Myelofibrosis. Invited. Xcenda. San Francisco, CA, US.
- 2012. Non-Transplant Treatment Aproaches in AML. Invited. Clavis Pharma ASA. New York, NY, US.
- 2012. Non-transplant treatment approaches for acute myeloid leukemia. Invited. 38th Annual Meeting of the European Group for Blood and Marrow Transplantation. Geneva, Switzerland, US.
- 2012. Data on Treatment Options for Myeloproliferative Disorders. Invited. AmerisourceBergen Consulting Service. Las Vegas, NV, US.
- 2012. Emerging Agents for AML. Invited. Post ASH Symposium. Kansas City, MO, US.
- 2012. Data on Treatment Options for Myloproliferative Disorders. Conference. Challenging Cases. New York, NY, US.
- 2011. Combination of the Hypercvad Regimen with Dasatinib in Patients with Relapsed Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL) or Lymphoid Blast Phase of Chronic Myeloid Leukemia (CML-LB). Conference. 53rd Annual American Society Hematology Meeting. San Deigo, CA, US.
- 2011. Activating Mutations of the FMS-Like Tyrosine Kinase-3 (FLT3) At Complete Response and Relapse in Patients with Acute Myeloid Leukemia. Conference. 53rd Annual American Society Hematology Meeting. San Diego, CA, US.
- 2011. Preliminary Clinical, Pharmacokinetic (PK) and Pharmacodynamic (PD) Results of the Safety Run-In Part of a Phase II Trial of Orally Available MEK-Inhibitor MSC1936369 in Patients (Pts) with Advanced Hematological Malignancies (HM). Conference. 53rd Annual American Society Hematology Meeting. San Deigo, CA, US.
- 2011. Long-Term Follow-up of Combined Hypercvad (hCVAD) Regimen with Dasatinib (Db) in the Front Line Therapy of Patients (pts) with Philadelphia Chromosome Positive (Ph+) Acute Lympoblastic Leukemia (ALL). Conference. 53rd Annual American Society Hematology Meeting. San Diego, CA, US.
- 2011. Detection of Minimal Residual Leukemia Predicts the Outcome of Patients with philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia Treated with Tyrosine Kinase Inhibitors Plus Chemotherapy. Conference. 53rd Annual American Society Hematology Meeting. San Diego, CA, US.
- 2011. Phase 1/2 Study of Sapacitabine and Decitabine Administered Sequentially in Elderly Patients with Newly Diagnosed AML. Conference. 53rd Annual American Society Hematology Meeting. San Diego, CA, US.
- 2011. Predictors of Outcome in Adult Patients with Acute Myeloid Leukemia in Frist Relapse. Conference. 53rd Annual American Society Hematology Meeting. San Diego, CA, US.
- 2011. Final Report of a Randomized Study of Decitabine Versus Conventional Care (CC) for Maintenance Therapy in Patients with Intermediate and High Risk Acute Myeloid Leukemia (AML) in First or Subsequent Complete Remission (CR). Conference. 53rd Annual American Society Hematology Meeting. San Diego, CA, US.
- 2010. Dynamics of Minimal Residual Leukemia After Combinations of the HyperCVAD Regimen with Imatinib or Dasatinib In Patients with Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia (poster presentation). Conference. 52nd Annual Meeting of American Society of Hematology. Orlando, FL, US.
- 2010. Phase II Study of All-Trans Retinoic Acid (ATRA), Arsenic Trioxide (ATO), with or without Gemtuzumab OzogamIcin (GO) for the Frontline Therapy of Patients with Acute Promyelocytic Leukemia (APL) (poster presentation). Conference. 52nd Annual Meeting of American Society of Hematology. Orlando, FL, US.
- 2010. Phase II Study of Sequential Therapy with Cladribine Followed by an Extended Course Rituximab in Patients with Hairy Cell Leukemia (poster presentation). Conference. 52nd Annual Meeting of American Society of Hematology. Orlando, FL, US.
- 2010. Prognostic Significance of Mutations In Isocitrate Dehydrogenase (IDH) Enzyme Isoforms 1 and 2 and Single Nucleotide Polymorphisms (SNP) In IDH1, In Patients with Acute Myeloid Leukemia Treated with High Dose Cytarabine and Idarubicin Induction (poster presentation). Conference. 52nd Annual Meeting of American Society of Hematology. Orlando, FL, US.
- 2010. Preliminary Clinical, Pharmacokinetic (PK) and Pharmacodynamic (PD) Results of the Safety Run In Part of a Phase II Trial of the Orally Available MEK-Inhibitor MSC1936369 In Patients with Advanced Hematological Malignancies (poster presentation). Conference. 52nd Annual Meeting of American Society of Hematology. Orlando, FL, US.
- 2010. Recent advances in diagnosis and treatment of AML. Conference. The Scripps Clinic Review. La Jolla, CA, US.
- 2010. Treatment of acute myeloid leukemia (Session Chair). Conference. Leukemia. Houston, TX, US.
- 2010. Acute Promyelocytic Leukemia. Invited. CME Presentations - Fox Chase Cancer Center, Philadelphia, PA; Scripps Clinic, La Jolla, CA; University of Michigan, Ann Arbor, US.
- 2009. Combination of the Hypercvad Regimen with Dasatinib Is Effective in Patients with Relapsed Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL) and Lymphoid Blast Phase Chronic Myeloid Leukemia (CML-LB) (poster presentation). Conference. 51st Annual Meeting American Society of Hematology. New Orleans, LA, US.
- 2009. Phase I study of JAK2 inhibitor with INCB018424 in refractory leukemia (oral presentation). Invited. 51st Annual Meeting of American Society of Hematology. New Orleans, LA, US.
- 2009. Significant Activity of the JAK2 Inhibitor, INCB018424 in Patients with Secondary, Post-Myeloproliferative Disorder (MPD) Acute Myeloid Leukemia (sAML): Results of An Exploratory Phase II Study (oral presentation). Conference. 51st Annual Meeting of American Society of Hematology. New Orleans, LA, US.
- 2009. Characteristics and Outcome of Patients with Acute Myeloid Leukemia (AML) Refractory to One Cycle of High Dose Cytarabine-Based Induction Chemotherapy (poster presentation). Conference. 51st Annual Meeting American Society of Hematology. New Orleans, LA, US.
- 2009. Phase II Study of Combination of the Hypercvad Regimen with Dasatinib in the Front Line Therapy of Patients with Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL) (oral presentation). Conference. 51st Annual Meeting of American Society of Hematology. New Orleans, LA, US.
- 2009. A Phase 2 Dose Regimen Optimization Study of Three Schedules of Voreloxin as Single Agent Therapy for Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia (poster presentation). Conference. 51st Annual Meeting of American Society of Hematology. New Orleans, LA, US.
- 2008. Outcome of Ph+ ALL patients treated with hyper CVAD + Dastinib Oral mercitat (oral presentation). Invited. 50th Annual Meeting of American Society of Hematology. San Francisco, CA, US.
- 2008. Combination of Sorafenib, Idarubicin, and Cytarabine has a high response rate in Patient Newly Diagnosed Acute Myeloid Leukemia (AML) Younger Than 65 Years (oral presentation). Invited. 50th Annual Meeting of American Society of Hematology. San Francisco, CA, US.
- 2006. Alemtuzumab and pentostatin in T-lymphoid leukemias. Invited. Chemotherapy Foundation Symposium XXIV. New York City, NY, US.
- 2005. Chemo-immunotherapy for Indolent Lymphoid Malignancies other than CLL. Invited. 2005 Pan Pacific Lymphoma Conference. Kauai, HI, US.
- 2004. Long term follow-up of patients with hairy cell leukemia (HCL). Invited. 46th Annual Meeting of American Society of Hematology. San Diego, CA, US.
- 2004. New Targeted Therapies in Leukemia. Invited. Children's Oncology Group Meeting. Washington, US.
International Presentations
- 2017. How I treat ALL Ph - positive & similar - Alcantara. Invited. Amgen. Cancun, MX.
- 2017. Towards curative drug therapy for Ph+ALL. Invited. HUS, Helsinki University Hospital Comprehensive Cancer Center. Helsinki, FI.
- 2017. Targeted Treatment of AML. Conference. Eurasian Hematology Congress. Madrid, ES.
- 2015. Ph2 data (t/n AML) of SGI-110. Conference. SGI-110-04 Investigators' Meeting. Tokyo, JP.
- 2015. PNH: Biology and Treatment in 2015. Conference. Eurasian Hematology Congress. Istanbul, TR.
- 2015. Clinical importance and therapeutic implications of minimal residual disease. Conference. International Academic Oncology Meeting. Cancun, MX.
- 2015. CLL - treatment strategies in the era of novel agents. Conference. International Conference on Advances in Hematology and Oncology. Coeur D'Alene, US.
- 2013. Decitabine Based Therapy in Eldery AML. Conference. Haematocon 2013. Mumbai, IN.
- 2013. Advances in Treatment of Ph+ve ALL. Conference. Haematocon 2013. Mumbai, IN.
- 2013. Relapsed AML: Can we predict who will do well and what is the best therapy. Invited. Haematocon 2013. Mumbai, IN.
- 2013. Leukemia, Myelodysplasia and Transplantation. Conference. Hemato-Oncology Conference. Cancun, MX.
- 2013. How do new molecular markers influence treatment-decision in AML. Conference. Hemato-Oncology Conference. Cancun, MX.
- 2013. Mutational analysis impact on transplant outcomes AML/MDS. Conference. Hemato-Oncology Conference. Cancun, MX.
- 2013. Newly diagnosed CML in Chronic Phase: Treatment response and survival. Conference. The Hemato-Oncology Conference. Cancun, MX.
- 2013. Hematological Malignancies. Invited. Dr. Peter Townley Midwest Regional ASCO Review. Omaha, US.
- 2013. LLA: State of Art. Invited. Leukosummit 2013, MX.
- 2012. Can We Cure Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia without an Allogeneic Stem Cell Transplant. Invited. 2nd Emirates Haematology Conference. Abu Dhabi, SA.
- 2011. Role of FLT3 kinase inhibitors in AML. Conference. Leukemia 2011. Dobrovnik, SI.
- 2011. ASCO poster discussant - New Agents in Acute Myeloid Leukemia (speaker). Conference. ASCO 47th Annual Meeting. Chicago, US.
- 2011. Treatment of older patients with AML. Conference. Quebec Medical Association of Hematologists and Medical Oncologists. Quebec, AF.
- 2011. Initial of Studies of Voseroxin in Leukemia. Conference. Sunesis Advisory Board. Budapest, HU.
- 2010. Best of ASCO. Conference. ASCO. Cancun, MX.
- 2010. Advances in acute myeloid leukemia and progress in the treatment of Ph+ ALL. Conference. Hematology-Oncology conference. Puerto Vallarta, MX.
- 2010. Best of ASCO. Conference. ASCO. San Francisco, US.
- 2010. Acute myeloid leukemia in the elderly: who should be treated and with what? (Educational Session Speaker). Invited. ASCO 46th Annual '10 Meeting. Chicago, US.
- 2010. Randomized study of decitabine versus conventional care (CC) in patients (pts) with intermediate- and high-risk acute myeloid leukemia (AML) in first or subsequent complete remission (CR) (poster presentation). Conference. ASCO 46th Annual '10 Meeting. Chicago, US.
- 2009. Acute Promyelocytic Leukemia, Managment without chemotherapy. Conference. World Concology Congress. San Francisco, US.
- 2009. Advances in acute myeloid leukemia and progress in the treatment of Ph+ ALL. Conference. Hematology-Oncology Conference. Puerto Vallarta, MX.
- 2009. Best of ASCO. Conference. ASCO. Panama City, US.
- 2009. Phase I/II study of idarubicin (Ida), high-dose ara-C, and sorafenib (S) in patients (pts) younger than 65 years with acute myeloid leukemia (AML) (poster presentation). Conference. ASCO 45th Annual '09 Meeting. Orlando, US.
- 2008. Advances in acute myeloid leukemia and progress in the treatment of Ph+ ALL. Conference. Hematology-Oncology conference. Puerto Vallarta, MX.
- 2007. Advances in acute myeloid leukemia and progress in the treatment of Ph+ ALL. Conference. Hematology-Oncology conference. Puerto Vallarta, MX.
- 2005. Phase II study of cladribine (2CDA) followed by rituximab for eradication of minimal residual disease (MRD) in hairy cell leukemia (HCL). Invited. American Society of Clinical Oncology Conference. Orlando, US.
- 2005. Future directions in the treatment of CML. Invited. Royal Victoria Hospital. Montreal, CA.
- 2005. Future directions in the treatment of CML. Invited. Quebec Oncology Symposium. Montreal, CA.
- 2004. Long term follow-up with patients with T-prolymphocytic leukemia. Invited. American Society of Clinical Oncology. New Orleans, US.
Formal Peers
- 2017. Update in the management of acute myeloid leukemia. Invited. Vanderbilt-Ingram Cancer Center. Nashville, TN, US.
- 2010. Recent Development in the Treatment of Philadelphia Chromosome Postitive ALL. Invited. John Hopkins Medical School. Baltimore, US.
- 2010. Acute Promyelocytic Leukemia. Invited. Fox Chase Cancer Center. Philadelphia, US.
- 2010. Acute Promyelocytic Leukemia. Invited. Wake Forest University School of Medicine. Winston-Salem, NC, US.
- 2010. Acute Promyelocytic Leukemia. Invited. University of Michigan. Ann Arbor, MI, US.
- 2010. Recent Developments in the Treatment of Philadelphia Chromosome Positive ALL. Invited. MD Anderson. Houston, US.
- 2010. Progress in Acute Myeloid Leukemia. Invited. Moffitt Cancer Center, US.
- 2010. Progress in Acute Myeloid Leukemia. Invited. Baylor College of Medicine. Houston, US.
- 2009. Progress in Acute Myeloid Leukemia. Invited. UCLA, US.
- 2009. Progress in Acute Myeloid Leukemia. Invited. Drexel University College of Medicine, US.
- 2009. Progress in Acute Myeloid Leukemia and Myelodysplastic Syndromes. Invited. RUSH Medical Center, US.
- 2009. Progress in Acute Myeloid Leukemia and Myelodysplastic Syndromes. Invited. City of Hope Medical Center, US.
Grant & Contract Support
| Date: | 2021 - 2023 |
| Title: | Identifying Germline Risk Alleles in Families with Hairy Cell Leukemia and other Hematologic Cancers |
| Funding Source: | LLS Hairy Cell Leukemia Foundation |
| Role: | Co-I |
| ID: | FP00013448 (GODLEY) |
| Date: | 2018 - Present |
| Title: | 2018-0596- A Phase 1 First-In-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of AMG 427 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia |
| Funding Source: | Amgen |
| Role: | PI |
| ID: | 56035 |
| Date: | 2018 - 2021 |
| Title: | 2017-0313- Phase I/II Study of the Combination of Venetoclax (ABT-199), Ponatinib and Corticosteroids in Patients with Philadelphia Chromosome (Ph)-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL) and Lymphoid Blast Phase Chronic Myelogenous Leukemia |
| Funding Source: | Abbvie |
| Role: | PI |
| ID: | 55218 |
| Date: | 2017 - 2020 |
| Title: | 2017-0027 - CP-MGD006-01: A Phase 1, First-in-Human, Dose Escalation Study of MGD006, A CD123 x CD3 Dual Affinity Re-Targeting (DART) Bi-Specific Antibody-Based Molecule, in Patients with Relapsed or Refractory Acute Myeloid Leukemia or Intermediate-2/High Risk Myelodysplastic Syndrome |
| Funding Source: | MacroGenics |
| Role: | PI |
| ID: | 54560 |
| Date: | 2017 - 2020 |
| Title: | 2017-0365 - A Phase 1 First-In-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of AMG 673 Administered as Short Term Intravenous Infusions in Subjects With Relapsed/Refractory Acute Myeloid Leukemia |
| Funding Source: | Amgen |
| Role: | PI |
| ID: | 54912 |
| Date: | 2017 - 2018 |
| Title: | 2016-0454 - A Phase 1 study of SGN-CD123A in patients with relapsed or refractory |
| Funding Source: | SeattleGenetics |
| Role: | PI |
| ID: | SGN123-001(Ravandi) |
| Date: | 2016 - 2021 |
| Title: | 2016-0713 - A Phase I/II Study of SEL24 in Patients with Acute Myeloid Leukemia |
| Funding Source: | Selvita |
| Role: | PI |
| ID: | RCTS#53795 |
| Date: | 2016 - 2020 |
| Title: | 2016-0291 - A Phase I, Three-part Study to determine the Maximum Tolerated Dose/Recommended Dose (Part 1), Compare Bioavailability in the Fed and Fasted States (Part 2), and Evaluate Safety and Tolerability (Part 3) of a Novel Oral Arsenic Trioxide Formulation (ORH-2014), in Subjects with Advanced Hematological Disorders |
| Funding Source: | Orsenix Holdings |
| Role: | PI |
| ID: | ORH2014-001(Ravandi) |
| Date: | 2016 - 2019 |
| Title: | 2016-0102 - Areandomized, double-blind phase 3 study of vadastuximab talirine (SGN-CD33A) versus placebo in combination wiht azacitidine or decitabine in the treatment of older patients with newly diagnosed acutte myeloid leukemia |
| Funding Source: | SeattleGenetics |
| Role: | PI |
| Date: | 2016 - 2021 |
| Title: | 2016-0165 - A Phase 1Multple Dose Study to Evaluate the Safety and Tolerability of XmAb14045 in Patients with CD123-Expressing Hematologic Malignancies |
| Funding Source: | Xencor |
| Role: | PI |
| Date: | 2015 - Present |
| Title: | 2015-0296 Phase I first-in-human study Evaluating the Safety, Tolerability Pharmacokinetics, Pharmacodynamics and Efficacy of AMG 330 Administered as Continuous Intravenous Infusion in Subjects with Relapsed/Refractory Acute Myeloid Leukemia |
| Funding Source: | Amgen, Inc |
| Role: | PI |
| ID: | Coeus 15507 |
| Date: | 2015 - 2019 |
| Title: | 2014-0907- Phase I-II study of Idarubicin, Cytarabine, and Nivolumab in patients with high-risk MDS and AML |
| Funding Source: | Bristol-Myers Squibb Co |
| Role: | PI |
| ID: | 39930 |
| Date: | 2015 - 2018 |
| Title: | 2014-0744: A Phase 1b dose-escalation study of SGN-CD33A in combination with standard-of-care for patients with newly diagnosed acute myeloid leukemia (AML) |
| Funding Source: | Seattle Genetics |
| Role: | PI |
| ID: | 13484 |
| Date: | 2015 - 2018 |
| Title: | 2014-0858: An Open-Label Phase 2 Prospective, Randomized, Controlled Study of CLT-008 Myelodi Progenitor Cells as a Supportive Care Measure During Induction Chemotherapy for Acute Myeloid Leukemia |
| Funding Source: | Cellerant |
| Role: | PI |
| ID: | 13757 |
| Date: | 2014 - 2020 |
| Title: | 2014-0344: Study of Ruxolitib Plus Decitabine in Patients with Post Myeloproliferative Neoplasm - Acute Myeloid Leukemia |
| Funding Source: | InCyte |
| Role: | PI |
| ID: | 12473 |
| Date: | 2014 - 2017 |
| Title: | 2014-0615: A Phase 1 Trial of SGn-CD33A in patients with CD33-positivie acute myeloid leukemia |
| Funding Source: | Seattle Genetics |
| Role: | PI |
| ID: | 12728 |
| Date: | 2014 - 2017 |
| Title: | 2013-0116 "A Phase I/II Trial of MEK Inhibitor ARRY 162 in Subjects with Relapsed and or Refractory Leukemias and Patients with Poor Prognosis Acute Myeloid Leukemia Not Suitable for or Unwilling to Receive Standard Therapy" |
| Funding Source: | Array |
| Role: | PI |
| ID: | 7749 |
| Date: | 2014 - 2015 |
| Title: | 2012-1017 A Randomized Phase II Study of Two Schedules of Decitabine for Frontline Therapy of Older or Unfit Patients with Acute Myeloid Leukemia (AML) |
| Funding Source: | MDACC HI-CRSP |
| Role: | PI |
| ID: | 01 |
| Date: | 2013 - 2016 |
| Title: | 2012-1143 "Phase I/II Study of of Moxetumomab in Patients with relapsed and/or refractory Acute Lymphoblastic Leukemia (ALL)" |
| Funding Source: | MedImmune |
| Role: | PI |
| ID: | 7084 |
| Date: | 2013 - 2014 |
| Title: | CTEP 9355 2013-0302: A Pivotal Multicenter Trial of Moxetumomab pasudotox in Relapsed/Refractory Hairy Cell Leukemia |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | N01-CM-2011-00039 |
| Date: | 2013 - 2016 |
| Title: | CTEP 9268 2013-0299: A Multicenter Phase 2 Study of the Bruton's Tyrosine Kinase Inhibitor PCI-32765 for Treatment of Relapsed Hairy Cell Leukemia |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | N01-CM-2011-00039 |
| Date: | 2013 - 2018 |
| Title: | SPORE in Leukemia Project 1: Epigenetics and Epigenetic Therapy in AML |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 5 P50 CA100632-12 |
| Date: | 2013 - 2020 |
| Title: | 2013-0099: A Phase I/II Study of Vosaroxin and Decitabine in Older Patients with Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome |
| Funding Source: | Sunesis |
| Role: | PI |
| ID: | CS2013-37435 |
| Date: | 2013 - 2015 |
| Title: | 2012-1180 "A Phase I/II Trial of CLT-008 Myeloid Progrenitor Cells in Patients Receiving Chemotherapy for Leukemia or Myelodysplasia" |
| Funding Source: | Cellerant |
| Role: | PI |
| ID: | CS2012-37335 |
| Date: | 2013 - 2016 |
| Title: | ACS Mentored Research Scholar Grant: Germline Telomere Length and Telomerase Associated Gene Variants in Pediatric Acute Myeloid Leukemia (AML) |
| Funding Source: | ACS |
| Role: | Co-I |
| ID: | 01 |
| Date: | 2012 - Present |
| Title: | 2012-0866: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Compare Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care versus Best Supportive Care as Maintenance in AML in complete remission |
| Funding Source: | Celgene |
| Role: | Collaborator |
| ID: | 6195 |
| Date: | 2012 - 2015 |
| Title: | Germline Telomere Biology Defects in Pediatric and Young Adult Acute Myeloid Leukemia |
| Funding Source: | Baylor College of Medicine |
| Role: | Mentor |
| ID: | 5K23CA158148-02 |
| Date: | 2012 - 2016 |
| Title: | ACS Mentored Research Scholar: Germline Telomere Length and Telomerase Associated Gene Variants in Pediatric Acute Myeloid Leukemia (AML) |
| Funding Source: | Baylor College of Medicine/ACS |
| Role: | Co-I |
| Date: | 2012 - 2015 |
| Title: | 2012-0434 "A Phase I/II Study of Low-Dose Cytarabine and Actinium-255 Hum 195 in Older Patients with Untreated Acute Myeloid Leukemia" |
| Funding Source: | Actinium |
| Role: | PI |
| ID: | CA2012-37046 |
| Date: | 2012 - 2017 |
| Title: | 2011-0547: A Phase 1 Study to Evaluate the Safety and Tolerability and Pharmacokinetic/Pharmacodynamics of MK-8242 Administered Alone and in Combination with Chemotherapy in Subjects with Recurrent Acute Myelogenous Leukemia |
| Funding Source: | Merck |
| Role: | PI |
| ID: | CS2011-35559 |
| Date: | 2012 - 2014 |
| Title: | Germline Telomere Length and Telomerase Associated Gene Variants in Pediatric Acute Myeloid Leukemia (AML) |
| Funding Source: | Baylor College of Medicine/ASH |
| Role: | Co-I |
| ID: | 01 |
| Date: | 2011 - 2014 |
| Title: | Telomere Length and Telomerase Mutations in Pediatric and Young Adult Acute Myeloid Leukemia |
| Funding Source: | NIH/NCI |
| Role: | Mentor |
| ID: | PA-10-060 K23 |
| Date: | 2011 - 2016 |
| Title: | 2010-0511: Phase II Study of Sorafenib and 5-Azacitidine for the Treatment of Patients with Refractory or Relapsed Acute Leukemia and Myelodysplastic Syndrome (MDS) - (VZ-MDS-PI-0227) |
| Funding Source: | Celgene |
| Role: | PI |
| ID: | CS2011-33724 |
| Date: | 2011 - Present |
| Title: | 2010-0981 - Phase II Study of Treatment of Acute Promyelocytic Leukemia (APL) with ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin (GO) |
| Funding Source: | Pfizer |
| Role: | PI |
| ID: | CS2011-00034949 |
| Date: | 2010 - 2015 |
| Title: | 2010-0692: A Phase 3, Randomized, Controlled Double-Blind, Multinational Clinical Study of the Efficacy and Safety of Vosaroxin and Cytarabine Versus Placebo and Cytarabine in Patients with First Relapsed or Refractory Acute Myeloid Leukemia (VALOR) |
| Funding Source: | Sunesis |
| Role: | PI |
| ID: | CS2011-33862 |
| Date: | 2010 - 2016 |
| Title: | 2010-0511: Phase II Study of Sorafenib and 5-Azacitidine for the Treatment of Patients with Refractory or Relapsed Acute Leukemia and Myelodysplastic Syndrome (MDS) - (VZ-MDS-PI-0227) |
| Funding Source: | Bayer |
| Role: | PI |
| ID: | CS2011-33759 |
| Date: | 2010 - 2014 |
| Title: | 2009-0785: A Phase 1 Study of LY2523355 in Patients with Acute Leukemia |
| Funding Source: | Eli Lilly |
| Role: | PI |
| ID: | CS2010-31681 |
| Date: | 2009 - 2014 |
| Title: | 2009-0196: A Dose Escalation Safety and Pharmacokinetic Study of SAR103168 Administered as a Single Agent by Intravenous Infusion, Once Daily for 5 Consecutive Days to Patients with Refractory/Relapsed Acute Myelogenous Leukemia |
| Funding Source: | Sanofi-Aventis |
| Role: | Principal Investigator-MDACC |
| ID: | CS2009-28552 |
| Date: | 2009 - 2014 |
| Title: | 2009-0195: Phase II Trial with Safety Run-in of MEK Inhibitor AS703026 in Subjects with Poor Prognosis Acute Myeloid Leukemia and Other Hematological Malignancies |
| Funding Source: | Serono |
| Role: | Principal Investigator-MDACC |
| ID: | CS2009-27713 |
| Date: | 2009 - 2014 |
| Title: | 2009-0131: Phase 1b/2, Open-Label, Multicenter, Dose-Escalating Clinical Study of the Safety, Tolerability, and Pharmacokinetic and Pharmacodynamic Profiles of Voreloxin Injection in Combination with Cytarabine in Patients with Relapsed or Refractory Acute Myeloid Leukemia |
| Funding Source: | Sunesis |
| Role: | PI |
| ID: | CS2009-28433 |
| Date: | 2008 - 2013 |
| Title: | 2007-0925: Phase II Study of INCB018424 in Patients with Advanced Hematologic Malignancies |
| Funding Source: | InCyte |
| Role: | PI |
| ID: | CS2008-23238 |
| Date: | 2008 - 2012 |
| Title: | 2007-0965: A Phase 2 Open-Label, Multicenter Clinical Study of the Safety and Efficacy of SNS-595 Injection in Patients Greater than or Equal to 60 Years of Age with Previously Untreated Acute Myeloid Leukemia |
| Funding Source: | Sunesis |
| Role: | Principal Investigator-MDACC |
| ID: | CS2008-23240 |
| Date: | 2008 - 2013 |
| Title: | Phase I Studies of Targeted Anti-Cancer Therapies; CTEP Protocol #6934 (DACC 2005-0607) "A Phase 1 Study of SJG-136 in Patients with Advanced Leukemia" |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 5 U01 CA062461-19 |
| Date: | 2007 - 2009 |
| Title: | 2006-0904: A Phase 3, Randomized, Double Blind, Multicenter Study of Proteinase 3 PR1 Peptide Mixed with Montanide ISA 51 VG Adjuvant and Administered with GM-CSF in Elderly Subjects with AML in First Complete Remission or Adults in Second Complete Remission: A Pivotal Study |
| Funding Source: | The Vaccine Company |
| Role: | Principal Investigator-MDACC |
| ID: | CS2007-20661 |
| Date: | 2007 - 2011 |
| Title: | 2006-0977: Phase I-II study of Idarubicin, Cytarabine, and Sorafenib (BAY43-9006), an oral VEGF, RAF and FLT3 inhibitor, in patients with high-risk MDS and AML |
| Funding Source: | Bayer |
| Role: | PI |
| ID: | CS2007-21416 |
| Date: | 2007 - 2010 |
| Title: | 2006-0939: EXamination of PNH, by Level Of CD59 on REd and white blood cells, in bone marrow failure syndromes (EXPLORE) |
| Funding Source: | Alexion |
| Role: | Principal Investigator-MDACC |
| ID: | CS2007-19594 |
| Date: | 2006 - 2008 |
| Title: | 2006-0595: A phase IIb, multicenter, open-label, nonrandomized, repeat-dose study of forodesine hydrochloride in patients with relapsed/refractory precursur T-Lymphoblastic Leukemia/Lymphoma who have failed two or more prior treatment regimens |
| Funding Source: | BioCryst |
| Role: | Principal Investigator-MDACC |
| ID: | CS2006-18439 |
| Date: | 2006 - Present |
| Title: | 2004-0223: Phase II Study of 2-Chlorodeoxyadenosine (2CDA) followed by Rituximab in Hairy Cell Leukemia |
| Funding Source: | Genentech |
| Role: | PI |
| ID: | CS2006-18009 |
| Date: | 2006 - Present |
| Title: | 2006-0478: Phase II study of combination of hyper-CVAD and dasatinib in patients with Philadelphia (Ph)- chromosome and/or BCR-ABL-positive acute lymphoblastic leukemia (ALL) |
| Funding Source: | Bristol-Myers Squibb |
| Role: | Principal Investigator-MDACC |
| ID: | CS2006-18008 |
| Date: | 2006 - 2012 |
| Title: | 2006-0358: Randomized study of decitabine versus observation as maintenance therapy for adults with unfavorable risk AML in first CR or adults with relapsed AML in second or greater CR |
| Funding Source: | MGI |
| Role: | PI |
| ID: | CS2006-17677 |
| Date: | 2006 - 2012 |
| Title: | 2006-0249: A phase I study of triciribine phosphate monohydrate (TCN-PM, VD-0002) in adult patients with advanced hematologic malignancies |
| Funding Source: | VioQuest |
| Role: | Principal Investigator-MDACC |
| ID: | CS2006-17351 |
| Date: | 2005 - 2010 |
| Title: | 2005-0271: A Phase I Study of Combination Therapy with Immunotoxins IMTOX 19 (IgG-HD37-SMPT-dgA) plus IMTOX 22 (IgG-RFB4-SMPT-dgA) in Adults with Refractory/Relapsed CD19 (+), CD 22 (+) B-Lineage Acute Lymphoblastic Leukemia |
| Funding Source: | Abiogen |
| Role: | Principal Investigator-MDACC |
| ID: | CS2006-15912 |
| Date: | 2005 - 2010 |
| Title: | Enhancing the Efficacy of Nucleoside Analogs |
| Funding Source: | NIH/NCI |
| Role: | Consult |
| ID: | 5R01 CA113843-04 |
| Date: | 2005 - 2009 |
| Title: | 2005-0290: Phase II Study of Forodesine Hydrochloride in Patients with Advanced, Fludarabine- Refractory Chronic Lymphocytic Leukemia (CLL) |
| Funding Source: | BioCryst |
| Role: | Principal Investigator-MDACC |
| ID: | CS2005-14900 |
| Date: | 2005 - 2010 |
| Title: | 2004-0408: A Phase II Study of Alemtuzumab and Pentostatin in T-Cell Neoplasms |
| Funding Source: | Berlex |
| Role: | PI |
| ID: | CS2004-12702 |
| Date: | 2005 - 2006 |
| Title: | MDACC Institutional Research grant |
| Funding Source: | UT M. D. Anderson Cancer Center |
| Role: | PI |
| Date: | 2005 - 2010 |
| Title: | 2004-0408: A Phase II Study of Alemtuzumab and Pentostatin in T-Cell Neoplasms |
| Funding Source: | Supergen |
| Role: | PI |
| ID: | CS2004-12716 |
| Date: | 2004 - 2009 |
| Title: | 2005-0115: Phase II Study of Combination of Thymoglobulin, Cyclosporine, Methylprednisone and GCSF in Patients with Severe Aplastic Anemia and Hypoplastic Myelodysplastic Syndrome |
| Funding Source: | Genzyme |
| Role: | PI |
| ID: | CS2005-12777 |
| Date: | 2004 - 2014 |
| Title: | Full Member Application Affiliated with SWOG |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 5 U10 CA105409-11 |
| Date: | 2003 - 2010 |
| Title: | 2003-719: A Randomized, Open-Label Study of Oral CEP-701 Administered in Sequence with Standard Chemotherapy to Patients with Relapsed Acute Myeloid Leukemia (AML) Expressing FLT-3 Activating Mutations" |
| Funding Source: | Cephalon |
| Role: | PI |
| ID: | CS2003-10100 |
| Date: | 2003 - 2004 |
| Title: | UIC Seed grant |
| Funding Source: | University of Illinois Campus Research Board |
| Role: | PI |
| Date: | 2002 - 2006 |
| Title: | Modification of deoxycytidine kinase to enhance anti-neoplastic activity of nucleoside analogs |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | R01 |
| Title: | Role of hypomethylating agents in the maintenance therapy of acute myeloid leukemia |
| Funding Source: | NIH/NCI |
| Role: | PI |
| Title: | ACRA in Hematologic Malignancies |
| Funding Source: | ACRA |
| Role: | PI |
| Title: | Maintenance therapy in acute myelogenous leukemia |
| Funding Source: | Leukemia and Lymphoma Society |
| Role: | PI |
| ID: | LLS Scholar in Clinical Research |
Patient Reviews
CV information above last modified April 11, 2025